Latest news with #ProphecyMarketInsights
Time Business News
14 hours ago
- Business
- Time Business News
Surge in Carbon Credit Platforms Signals Shift Toward Profitable Climate Action
The global Carbon Credit Trading Platform Market, valued at USD 146.2 million in 2024, is projected to surge to USD 724.0 million by 2035, growing at a robust CAGR of 17.6%. This growth is driven by increasing global focus on emissions reduction, rising corporate sustainability efforts, and a widespread shift toward achieving net-zero emissions targets. In a comprehensive analysis led by Shweta R., Business Development Specialist at Prophecy Market Insights, the evolving landscape of carbon trading platforms is explored in depth, highlighting market dynamics, opportunities, and competitive strategies. Carbon credit trading platforms enable organizations to offset their greenhouse gas emissions by purchasing carbon credits tied to verified environmental projects. These platforms are gaining momentum as governments implement stricter climate regulations and businesses prioritize environmental accountability. The market is segmented by type (voluntary and regulated markets), system type (cap-and-trade, baseline-and-credit), end-use industries (industrial, utilities, energy, petrochemical, aviation, and others), and by region. Several key factors are accelerating market growth: 1. Government and Intergovernmental Policies: Programs like the EU Emissions Trading System (EU ETS) and California's Cap-and-Trade initiative are compelling businesses to participate in carbon trading, expanding platform adoption. 2. Corporate Net-Zero Commitments: A growing number of multinational companies are setting voluntary net-zero goals, fueling demand for high-quality carbon credits and reliable platforms for tracking and compliance. Despite its potential, the market faces several challenges: · Lack of Standardization: Inconsistencies in carbon credit quality, verification methods, and pricing across markets create uncertainty. · Limited Awareness: Especially in developing regions, understanding of carbon trading remains low, and supporting infrastructure is still emerging. · Growth in Emerging Economies: Asia-Pacific and Latin America are seeing increased government support for carbon pricing. As policy frameworks and infrastructure develop, these regions will become key growth areas. · Decentralized Markets: Blockchain-based platforms are lowering entry barriers and improving transparency, creating opportunities for small-scale traders and new market entrants. The market includes a diverse mix of global exchanges, environmental consultancies, and tech-driven startups. Leading players include: · Nasdaq, Inc. · CME Group Inc. · ACX (AirCarbon Exchange) · XPANSIV · ClimeCo LLC · VERRA · South Pole · Rubicon Carbon Services · European Energy Exchange AG · Carbonplace · ClimateTrade · SCB Group · Cloverly · Envex · ecoact These companies are leveraging technologies such as AI for credit assessment, blockchain for traceability, and digital platforms to streamline trading processes. · North America leads the market, driven by strong regulatory support, corporate leadership in sustainability, and advanced digital infrastructure. · Europe is a close second, supported by comprehensive climate policies and the longstanding EU ETS framework. · Asia-Pacific is the fastest-growing region, propelled by industrial expansion and evolving environmental regulations in countries like China, India, and Japan. · Latin America and MEA are emerging markets, gaining traction with increased interest in climate finance and international carbon offset projects. To maximize growth potential, stakeholders should: · Invest in platform transparency through blockchain and third-party verification. · Engage with regulators to support consistent standards. · Promote education and awareness in underserved markets. As global efforts to combat climate change intensify, carbon credit trading platforms will become essential tools in achieving sustainability goals. With rapid digital transformation and regulatory alignment underway, this sector presents a high-growth opportunity for innovators, investors, and policymakers alike. TIME BUSINESS NEWS
Time Business News
14 hours ago
- Health
- Time Business News
Eczema Therapeutics Sector Forecast to Reach $49.8 Billion by 2035, Fueled by Breakthrough Biologics
The global eczema therapeutics sector is undergoing a significant transformation, propelled by the emergence of advanced biologic therapies and growing awareness around skin health. According to projections from Prophecy Market Insights, the sector is expected to surge from USD 19.5 billion in 2025 to USD 49.8 billion by 2035, reflecting a robust compound annual growth rate (CAGR) of 9.9%. At the forefront of this shift is the increasing incidence of eczema—particularly atopic dermatitis—affecting millions globally. Characterized by chronic inflammation, severe itching, and skin barrier dysfunction, eczema is most common in infants and children but can persist into or begin in adulthood. In the United States alone, over 31 million individuals are living with eczema, as reported by the National Eczema Association. Growth Catalysts The rising prevalence of eczema is a primary factor behind the sector's momentum. Pediatric cases continue to climb, while adult diagnoses are also increasing as awareness and diagnostic capabilities improve. Urbanization and lifestyle factors are further contributing to the surge in cases across both developed and developing economies. Recent years have seen a paradigm shift in treatment approaches, thanks to the approval and adoption of innovative biologics such as Dupixent (dupilumab) by Sanofi and Regeneron and Abrocitinib , a selective JAK1 inhibitor by Pfizer. These advanced therapies have proven especially effective for patients with moderate to severe eczema who do not respond well to conventional treatments like corticosteroids or calcineurin inhibitors. Barriers to Access Despite the progress, the eczema therapeutics landscape faces notable challenges. Chief among them is the high cost of biologic therapies, which can limit access, particularly in low- and middle-income regions. Additionally, traditional treatments, though widely used, often carry risks such as skin thinning and hormonal imbalances, which can deter long-term adherence and physician recommendations. Opportunities in Innovation and Emerging Regions The future of eczema care lies in personalized and targeted treatments. Innovations in genomics, microbiome research, and drug delivery are paving the way for more precise therapies with fewer side effects. Emerging economies present significant untapped potential, with expanding healthcare infrastructure, government support, and rising consumer awareness around dermatological conditions. Sector Segmentation The eczema therapeutics industry is segmented based on multiple parameters: By Drug Class: Including corticosteroids, calcineurin inhibitors, PDE4 inhibitors, and biologics. Including corticosteroids, calcineurin inhibitors, PDE4 inhibitors, and biologics. By Treatment Type: Prescription medications, over-the-counter (OTC) products, alternative therapies, and home-based remedies. Prescription medications, over-the-counter (OTC) products, alternative therapies, and home-based remedies. By Eczema Type: Atopic, contact, seborrheic, dyshidrotic, and nummular eczema. Atopic, contact, seborrheic, dyshidrotic, and nummular eczema. By Route of Administration: Topical applications dominate, followed by oral and injectable options. Topical applications dominate, followed by oral and injectable options. By Distribution Channel: Hospital pharmacies, retail outlets, and increasingly, online platforms. Hospital pharmacies, retail outlets, and increasingly, online platforms. By Patient Demographic: Infants, children, and adults form the primary treatment groups. Regional Outlook North America remains the global leader, benefiting from advanced healthcare systems, strong R&D activity, and favorable insurance reimbursement models. Europe also demonstrates strong momentum, especially in nations such as Germany, France, and the UK. The Asia-Pacific region is emerging as the fastest-growing geography, driven by urbanization, increased healthcare spending, and rising patient volumes in countries like India and China. Latin America, the Middle East, and Africa, while currently smaller in scale, are poised for steady progress as investments in healthcare infrastructure and dermatological services increase. Competitive Landscape The eczema therapeutics field is highly dynamic, with a blend of pharmaceutical giants and emerging biotech innovators. Key players include: Sanofi S.A. Regeneron Pharmaceuticals Pfizer Inc. AbbVie Inc. Novartis AG LEO Pharma A/S GlaxoSmithKline plc AstraZeneca plc Galderma SA Incyte Corporation These companies are actively developing new therapies aimed at improving efficacy, reducing side effects, and expanding access across age groups and severity levels. Recent Developments Pfizer's oral JAK1 inhibitor Abrocitinib gained FDA approval in 2023, enhancing treatment options for patients requiring systemic therapy. gained FDA approval in 2023, enhancing treatment options for patients requiring systemic therapy. Sanofi and Regeneron are expanding Dupixent's indications through clinical trials targeting adolescents and younger children. indications through clinical trials targeting adolescents and younger children. A wave of startups is pursuing microbiome-focused and gene-based therapies that promise long-term, sustainable relief with minimal adverse reactions. Looking Ahead With innovation at the forefront, the eczema therapeutics sector is set for accelerated growth through 2035. Biologic advancements, expanding global awareness, and precision medicine are redefining treatment standards, offering renewed hope to millions living with this chronic skin disorder. TIME BUSINESS NEWS
Yahoo
09-03-2025
- Health
- Yahoo
Experts predict perfect conditions for disease-carrying insects to thrive: 'Major driver'
Serious health challenges face communities, as our overheating planet creates perfect conditions for disease-carrying insects to thrive, according to market research of the vector control market by Prophecy Market Insights (and reported by OpenPR). This comes as health agencies worldwide have reported significant increases in mosquito, tick, and other vector-borne illnesses that once rarely appeared in many regions. Vector control, or the strategies used to manage disease-carrying insects and animals that transmit dangerous pathogens, protects millions of people worldwide from potentially deadly illnesses that thrive in warming climates. Vector-borne diseases are surging globally, with the World Health Organization reporting these illnesses now account for more than 17% of all infectious diseases, causing over 700,000 deaths annually. This health crisis has sparked massive growth in the vector control industry, which market researchers project will reach $41 billion by 2035. The changing climate directly contributes to this trend by expanding the geographic range of disease-carrying insects. Warmer temperatures allow mosquitoes, ticks, and other vectors to survive in previously inhospitable areas and extend their active season. "The rising incidence of vector-borne diseases, particularly in developing countries, is a major driver of the vector control market," noted the report from Prophecy Market Insights. These illnesses pose serious risks to community health, especially in areas with limited healthcare resources. Many regions now face threats from diseases they've never encountered before, leaving populations without natural immunity or established treatment protocols. Vector-borne diseases disproportionately affect vulnerable populations, including children, elderly people, and those with compromised immune systems. The health impacts range from mild fevers to life-threatening conditions affecting the brain, heart, and other vital organs. Urban environments face particular challenges as crowded living conditions and poor infrastructure create ideal breeding grounds for vectors. The CDC has documented worrying examples such as locally-acquired malaria cases in Florida for the first time in 20 years and the continued spread of West Nile virus across the United States. Do you worry about air pollution in and around your home? Yes — always Yes — often Yes — sometimes No — never Click your choice to see results and speak your mind. Per the article in OpenPR, "The future of the vector control market lies in the integration of technology, sustainability, and community engagement." While pesticide use may increase as communities battle these threats, many experts emphasize more sustainable approaches that balance immediate protection with long-term environmental health. Emerging biological controls and genetically modified techniques offer promising alternatives that target disease vectors without harming beneficial insects or contaminating water supplies. People can also make a difference through simple actions in their own homes and neighborhoods. Regularly emptying standing water from containers, installing window screens, and using EPA-approved repellents effectively reduce exposure to disease-carrying vectors. Community-led initiatives to monitor local mosquito populations and advocate for climate-resilient infrastructure have shown success in reducing disease transmission rates in high-risk areas. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
